Merck maintained revenues despite significant patent expiries, showcasing strong performance in core brands and emerging markets. However, the delay of the odanacatib filing to 2014 and cautious guidance for 2013 due to ongoing patent challenges may concern investors. These factors suggest potential short-term pressure on the stock price.

[-1]